ASC4START: A Phase 3b, open-label, randomized study of asciminib versus nilotinib in patients with newly diagnosed Ph plus Chronic Myelogenous Leukemia in Chronic Phase
ONCOLOGY RESEARCH AND TREATMENT（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要